19 May 2013
Keywords: UCB, Xyrem, Fibromyalgia, EMA, CHMP, Europe, Non-approval
Article | 18 March 2011
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) yesterday told Belgian drugmaker UCB ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 March 2011
17 March 2011
17 May 2013
© 2013 thepharmaletter.com